Debromohymenialdisine

CAS No. 75593-17-8

Debromohymenialdisine( SKF-108753 | SKF108753 )

Catalog No. M15875 CAS No. 75593-17-8

A marine sponge alkaloid that inhibits Chk1 and Chk2 with IC50 of 3 and 3.5 uM, respectively; also inhibits MAP kinase kinase 1 (IC50=881 nM), GSK3β (IC50=1.39 uM), and CDK5/p25 (IC50=9.12 uM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 1004 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Debromohymenialdisine
  • Note
    Research use only, not for human use.
  • Brief Description
    A marine sponge alkaloid that inhibits Chk1 and Chk2 with IC50 of 3 and 3.5 uM, respectively; also inhibits MAP kinase kinase 1 (IC50=881 nM), GSK3β (IC50=1.39 uM), and CDK5/p25 (IC50=9.12 uM).
  • Description
    A marine sponge alkaloid that inhibits Chk1 and Chk2 with IC50 of 3 and 3.5 uM, respectively; also inhibits MAP kinase kinase 1 (IC50=881 nM), GSK3β (IC50=1.39 uM), and CDK5/p25 (IC50=9.12 uM), does not significantly affect ATM and ATR; blocks G2 arrest in cancer cells.
  • In Vitro
    Debromohymenialdisine has moderate inhibitory activity with an IC50 value of 881 nM in the initial Raf/MEK-1/MAPK signaling cascade assay.
  • In Vivo
    ——
  • Synonyms
    SKF-108753 | SKF108753
  • Pathway
    Angiogenesis
  • Target
    Chk
  • Recptor
    Chk
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    75593-17-8
  • Formula Weight
    245.2
  • Molecular Formula
    C11H11N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(C1=C/2C=CN1)NCCC2=C3N=C(N)NC/3=O
  • Chemical Name
    (4Z)-4-(2-amino-1,5-dihydro-5-oxo-4H-imidazol-4-ylidene)-4,5,6,7-tetrahydro-pyrrolo[2,3-c]azepin-8(1H)-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Curman D, et al. J Biol Chem. 2001 May 25;276(21):17914-9. 2. Saleem RS, et al. Bioorg Med Chem. 2012 Feb 15;20(4):1475-81. 3. Jobson AG, et al. Mol Pharmacol. 2007 Oct;72(4):876-84.
molnova catalog
related products
  • PV-1115

    A potent and highly selective Chk2 inhibitor with IC50 of 0.14 nM; displays greater than 100 uM for Chk1 in vitro.

  • Monalizumab

    Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A).

  • CCT-245737

    A highly potent, selective, ATP-competitive inhibitor of Chk1 with IC50 of 1.3 nM; weak inhibition on Chk2 (IC50=2440 nM).